直肠癌放疗后心血管疾病短期与长期风险:四项随机对照试验与人群登记研究
该研究基于瑞典全国登记中14901例直肠癌患者及四项随机试验2675例患者,评估术前放疗与心血管疾病风险的关系。结果显示术前放疗未增加总体心血管疾病风险,但静脉血栓栓塞风险升高,尤其在术后6个月内。
要点
- 术前放疗未增加直肠癌患者总体心血管疾病风险。
- 放疗组静脉血栓栓塞风险升高,登记IRR=1.41(95%CI 1.15-2.72)。
- 2006-2009年抗血栓治疗引入后术后6个月内IRR=2.30(95%CI 1.01-5.21)。
核心结论
- 术前放疗不影响直肠癌患者总体心血管疾病风险。
- 放疗与静脉血栓栓塞风险升高相关,但绝对风险差异低。
研究设计与样本
- 研究基于瑞典全国登记中1995-2009年诊断的14901例直肠癌患者,其中9227例接受术前放疗。
- 另分析1980-1999年四项随机试验中2675例直肠癌患者,随机接受术前放疗或未放疗后手术。
- 采用多变量Cox回归估计无复发生存随访期间心血管疾病风险,登记和试验最大随访分别为18年和33年。
主要发现
- 登记中术前放疗与总体心血管疾病风险无关联(IRR=0.99,95%CI 0.92-1.06)。
- pooled试验中术前放疗与总体心血管疾病风险无关联(IRR=1.07,95%CI 0.93-1.24)。
- 登记中放疗组静脉血栓栓塞风险升高(IRR=1.41,95%CI 1.15-2.72)。
- 试验中放疗组静脉血栓栓塞风险升高(IRR=1.41,95%CI 0.97-2.04)。
- 2006-2009年抗血栓治疗引入后,术后6个月内静脉血栓栓塞IRR=2.30(95%CI 1.01-5.21)。
关键数值与推荐
- 静脉血栓栓塞归因于放疗的绝对率差低,为每1000患者年10例。
临床怎么用
- 术前放疗不增加总体心血管疾病风险,无需因此改变常规预防治疗。
- 对于已有高静脉血栓栓塞风险的患者,可考虑个体化预防策略。
局限性
- 研究基于登记和随机试验数据,可能存在未测量混杂因素。
- 静脉血栓栓塞的绝对风险差异低,需谨慎解释临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: A population-based cohort and four randomized trials enriched with long-term register data were used to clarify if radiotherapy in combination with rectal cancer surgery is associated with increased risks of cardiovascular disease (CVD). METHODS: We identified 14,901 rectal cancer patients diagnosed 1995-2009 in Swedish nationwide registers, of whom 9227 were treated with preoperative radiotherapy. Also, we investigated 2675 patients with rectal cancer previously randomized to preoperative radiotherapy or not followed by surgery in trials conducted 1980-1999. Risks of CVD overall and subtypes were estimated based on prospectively recorded hospital visits during relapse-free follow-up using multivariable Cox regression. Maximum follow-up was 18 and 33 years in the register and trials, respectively. RESULTS: We found no association between preoperative radiotherapy and overall CVD risk in the register (Incidence Rate Ratio, IRR = 0.99, 95% confidence interval (CI) 0.92-1.06) or in the pooled trials (IRR = 1.07, 95% CI 0.93-1.24). We noted an increased risk of venous thromboembolism among irradiated patients in both cohorts (IRRregister = 1.41, 95% CI 1.15-2.72; IRRtrials = 1.41, 95% CI 0.97-2.04), that remained during the first 6 months following surgery among patients treated 2006-2009, after the introduction of antithrombotic treatment (IRR6 months = 2.30, 95% CI 1.01-5.21). However, the absolute rate difference of venous thromboembolism attributed to RT was low (10 cases per 1000 patients and year). DISCUSSION: Preoperative radiotherapy did not affect rectal cancer patients' risk of CVD overall. Although an excess risk of short-term venous thromboembolism was noted, the small increase in absolute numbers does not call for general changes in routine prophylactic treatment, but might do so for patients already at high risk of venous thromboembolism.
引用
- Chen L, Eloranta S, Martling A, et al. Short- and long-term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population-based register. Radiother Oncol. 2018. PMID: 29306497. doi:10.1016/j.radonc.2017.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。